Expression and prongostic impact of galectin-7 in human lung cancer
Authors:
- Anna TirilomiATAnna Tirilomi
- Omar ElakadOEOmar Elakad
- Sha YaoSYSha Yao
- Marc HinterthanerMHMarc Hinterthaner
- Bernhard C. DannerBDBernhard C. Danner
- Philipp StröbelPSPhilipp Ströbel
- Theodor TirilomisTTTheodor Tirilomis
- Hanibal BohnenbergerHBHanibal Bohnenberger
- Alexander von Hammerstein-EquordAHAlexander von Hammerstein-Equord
Open Access
- 4 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (40) , e39911
Abstract
Malignant tumors of the lung are the leading cancers worldwide. Prognostic biomarkers continue to be investigated for the detection and stratification of lung cancer for clinical use. In breast cancer cells and in lymphomas, the overexpression of galectin-7 led to increased metastasis. In lung cancer, squamous cell carcinoma, galectin-7 was also identified as a factor promoting metastasis. In this study, we investigated the expression of galectin-7 in relation to clinicopathological features and overall survival in patients with different types of lung cancer. By immunohistochemistry, expression of galectin-7 was analyzed in 308 cases of lung cancer; 108 cases of adenocarcinoma, 193 cases of squamous cell lung carcinoma and 7 cases of small cell lung cancer (SCLC) and correlated with clinicopathological characteristics as well as patients’ overall survival. Immunohistochemical detection of galectin-7 expression was most evident in squamous cell lung carcinoma (36.27%), followed by adenocarcinoma (5.55%). Negative expression of galectin-7 was found in all patients with SCLC. No significant correlation was found in patients with squamous cell lung carcinoma. Within the adenocarcinoma and squamous cell lung carcinoma subgroups, there were statistically significant correlations between the expression of galectin-7 and some clinicopathologic features of the patients. In our study, we were able to show that galectin-7 could serve as a new prognostic biomarker and is also a potential new drug target in non-small cell lung cancer.Keywords
This publication has 30 references indexed in Scilit:
- Identification of Galectin-7 as a crucial metastatic enhancer of squamous cell carcinoma associated with immunosuppressionOncogene, 2022
- Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-AnalysisClinical Breast Cancer, 2022
- Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trialThe Lancet, 2022
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Targeted Therapy and Checkpoint Immunotherapy in Lung CancerSurgical Pathology Clinics, 2020
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017JAMA Oncology, 2019
- A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2019
- Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cellsOncogene, 2003
- A model for p53-induced apoptosisNature, 1997
- Galectin-7, a Human 14-kDa S-Lectin, Specifically Expressed in Keratinocytes and Sensitive to Retinoic AcidDevelopmental Biology, 1995